Maui Sky – Lifestyle
Author:
Organogenesis Holdings Inc.
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
April 28, 2026
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
April 7, 2026
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
April 7, 2026
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
April 6, 2026